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In 2010 a new Lagovirus related to rabbit haemorrhagic disease virus (RHDV) emerged in France and has since rapidly
spread throughout domestic and wild rabbit populations of several European countries. The new virus, termed RHDV2,
exhibits distinctive genetic, antigenic and pathogenic features. Notably, RHDV2 kills rabbits previously vaccinated with
RHDV vaccines. Here we report for the first time the generation and characterization of RHDV2-specific virus-like
particles (VLPs). Our results further confirmed the differential antigenic properties exhibited by RHDV and RHDV2,
highlighting the need of using RHDV2-specific diagnostic assays to monitor the spread of this new virus.Introduction, methods and results
Rabbit haemorrhagic disease (RHD) is a highly infectious
and fatal disease of the European rabbit (Oryctolagus
cuniculus), (reviewed in [1]). The etiological agent, rabbit
haemorrhagic disease virus (RHDV), belongs to the
Lagovirus genus within the Caliciviridae family. This
genus comprises several non-pathogenic rabbit calici-
viruses, which are genetically related to but relatively
distant from RHDV [2,3], and European brown hare syn-
drome virus (EBHSV). RHDV is highly contagious and
usually fatal in adult rabbits, with a mortality range up
to 80-100% [4]. Susceptibility to the disease begins in
the 5-6th week of life of rabbits and steadily increases up
to the 8-9th week when they become fully susceptible.
After it was reported in China in 1984, RHD spread rap-
idly around the world, being currently enzootic in wild
rabbit populations in Europe, Australia and New
Zealand. When it emerged, RHD dramatically reduced
wild rabbit populations and was responsible for great
economic losses in the rabbit industry worldwide [1].
Subsequently, efficient inactivated commercial vaccines
against RHDV were introduced in the early 1990s, provid-
ing a good coverage, since all circulating strains are* Correspondence: barcena@inia.es; alejo@inia.es
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the control of RHD in rabbitries for the last 20 years. Like-
wise, ELISA methods developed in Italy for the veterinary
diagnosis of RHD in domestic rabbits [4,5], were proven
effective tools for monitoring RHDV field epidemiology,
particularly in surveys conducted in Australia among wild
rabbit populations [6,7].
RHDV is a non-enveloped icosahedral single-stranded
positive-sense RNA virus. The virus capsid (~40 nm
diameter) comprises 90 dimers of a single capsid sub-
unit, the VP60 protein. RHDV as most caliciviruses can-
not be grown in cell culture, a fact that has hampered
the study of this group of viruses, as well as the develop-
ment of control measures. A major breakthrough was
the finding that expression of recombinant VP60 protein
in insect cells results in the formation of virus-like parti-
cles (VLPs) that are morphologically and antigenically
identical to infectious RHDV virions [8]. RHDV VLPs
have been shown to induce full protection of rabbits
against a lethal challenge with RHDV [9,10]. These VLPs
have also been used for the development of sensitive and
reliable tests for detection of antibodies to RHDV [9,11].
The VP60 protein has three domains [12], an N-terminal
arm (NTA), a shell (S) forming a scaffold which protects
the viral RNA, and a flexible protruding domain (P) at the
capsid surface, which contains determinants for virus-host
receptor interactions and antigenic diversity [12,13]. The Pe is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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with P2 subdomain located at the outermost surface-
exposed region of the viral capsid.
In 2010 a new RHDV related virus with a distinctive
pathogenic profile was identified in France [14,15] and
has since rapidly spread throughout domestic and wild
rabbit populations of Italy, Spain, Portugal Germany,
United Kingdom and the Azores islands [14,16-21]. Unlike
RHDV, the new lagovirus, termed RHDV2 or RHDVb in
the literature, kills rabbit kits under 30 days of age, as well
as rabbits that had been previously vaccinated against
RHDV. Further studies have pointed out other distinctive
features of RHDV2: it causes an average mortality of 20%
in experimentally infected rabbits [14], which is consist-
ently less than RHDV, and exhibits a broader host range,
since it infects other lagomorphs like different hare species
[17,22], causing an RHD-like disease. RHDV2 has specific
genetic and antigenic profiles. It has been shown that sev-
eral monoclonal antibodies (MAbs) against RHDV capsid
protein fail to react with cognate RHDV2 virions [14,17].
The situation originated by the emergence of RHDV2
virus has raised concerns regarding the impact of the
new disease among domestic and wild rabbit popula-
tions [23]. Given the serious epizootic situation created,
new inactivated vaccines against RHDV2 have been ur-
gently developed and their use has been provisionally
allowed in European Union member states. Recently, the
World Organization for Animal Health (OIE) Reference
Laboratory for RHD (IZSLER, Brescia, Italy), has devel-
oped a serological assay based on the use of specific anti-
RHDV2 MAbs, rabbit immune serum and virus capsid
antigen obtained from RHDV2-infected rabbit liver ex-
tracts [22].
Here we report for the first time the generation and
characterisation of RHDV2-specific VLPs, and their use
together with RHDV-specific VLPs, to conduct a com-
parative serological study involving sera from vaccinated
and virus-infected rabbits. Our results further confirmed
the differential antigenic properties exhibited by RHDV
and RHDV2 virus capsids, highlighting the need for
using specific serological assays as tools to monitor the
epidemiology of this emergent virus, where virus-
specific VLPs could represent a convenient alternative to
classical virus antigen.
We generated a recombinant baculovirus expressing the
RHDV2 VP60 protein. For comparative purposes, a baculo-
virus expressing RHDV VP60 was generated in parallel.
Codon-optimized genes for expression in insect cells of the
RHDV (strain Ast89, GenBank accession no. Z49271) and
RHDV2 (strain Vs11, GenBank accession no. JX106023)
VP60 proteins were synthesised (GenScript, USA) and sub-
cloned into BglII/EcoRI digested plasmid pHAPh2GS [24].
Recombinant baculoviruses were obtained by cotransfec-
tion with the flashBACULTRA linearized baculoviralgenome (Oxford expression technologies, UK) as indi-
cated by the manufacturer. Both VP60 proteins were
expressed to grossly similar levels in infected H5 in-
sect cells (not shown). Subsequently, in order to de-
termine whether the VP60 constructs were able to
assemble into particulate material, infected-cell ex-
tracts were subjected to a VLP-purification protocol
as previously described [25]. As shown in Figure 1A,
both VP60-derived assemblies were purified to near
homogeneity. Electron microscopy analysis of nega-
tively stained preparations revealed that both, RHDV
and RHDV2-derived VP60 proteins assembled with
similar efficiency into VLPs of approximately 40 nm
in diameter (Figure 1B), which were morphologically
identical to previously described RHDV VLPs [8,26].
As a first step in the assessment of the antigenic profile
of both lagovirus VLPs, we evaluated their reactivity with
a panel of three MAbs, raised against RHDV VLPs in our
laboratory following previously described procedures [27].
We also included in this analysis the capsid protein of
EBHSV, expressed in the baculovirus expression system,
available in our laboratory. The MAbs had been previously
characterized by assessing their reactivity with a set of
RHDV VP60 deletion mutants, as well as a set of overlap-
ping peptides encompassing the complete P2 subdomain
(unpublished results). The analysis was performed using
an indirect ELISA assay. Briefly, purified VLPs (0.5 μg/mL
in PBS buffer) were absorbed to Nunc Polysorp ELISA
plates. Next, serial three-fold dilutions of the MAbs (hy-
bridoma supernatants) were added to the wells, followed
by addition of HRP-conjugated goat anti-mouse IgG
(H + L) (Invitrogen) at a 1/3000 dilution. Table 1 summa-
rizes the results obtained. MAb 2E7, which recognizes a
linear epitope located at the C-terminal end of VP60 pro-
tein (within aa positions 549-579), at the P1 subdomain,
reacted with the three lagovirus capsid proteins tested.
MAb 1G5, which recognizes a linear epitope with the se-
quence: NPISQVAP (aa positions 326-333 of VP60 pro-
tein) located at loop L2 of P2 subdomain, reacted with
both, RHDV and RHDV2 capsid proteins, but not with
the cognate EBHSV capsid protein. Finally, MAb 1C9
reacted only with the RHDV capsid protein. This MAb
binds to a conformational epitope, as it does not react
with RHDV capsid protein in Western blot, or in ELISA
assays where the VP60 protein was denatured by treat-
ment with 7 M urea before adsorption. Interestingly, MAb
1C9 does not bind to modified RHDV VLPs, derived from
VP60 deletion or insertion mutants, lacking the amino
acid sequence PGNNAT, which corresponds to aa posi-
tions 305-310, and is located within loop L1 at the tip of
the P2 subdomain of the VP60 protein. These results were
consistent with the available information regarding se-
quence alignment studies of lagovirus capsid proteins
[3,14,28], which indicate the regions recognized by MAbs
Figure 1 The RHDV2 recombinant capsid protein assembles into VLPs. A Coomassie blue stained SDS-PAGE of purified recombinant RHDV
and RHDV2 VP60 proteins. Molecular weight markers (MWM) are given on the left (×103 Da). B Electron micrographs of negatively stained samples of
RHDV and RHDV2 purified VP60 particles. Scale bar, 100 nm.
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tested, while the sequence corresponding to aa 305-310,
critical for MAb 1C9 binding, lies within variation region
V1 [12,14], one of the seven highly variable regions de-
fined on VP60 capsid protein, which has been shown to
constitute a major neutralization site [12]. Altogether,
these data suggests MAb 1C9 targets an antigenically rele-
vant epitope on the RHDV capsid, not present in RHDV2,
which deserves further characterization.
We then assessed whether polyclonal rabbit sera might
also recognize RHDV and RHDV2 capsids differently.
To this end, rabbit hyperimmune sera raised against
RHDV VLPs were tested by indirect ELISA against both
RHDV and RHDV2 VLPs. Briefly, RHDV or RHDV2
VLPs (0.5 μg/mL in PBS buffer) were absorbed to Nunc
Polysorp ELISA plates. Next, sera obtained from rabbits
inoculated four times with 500 μg of RHDV VLPs emul-
sified in Montanide ISA 50 V2 (Seppic, France), were
assayed using seven serial three-fold dilutions starting
from 1/10 000. Subsequently, the secondary antibodyTable 1 Reactivity of anti-RHDV MAbs against the capsid
proteins of RHDV, RHDV2 and EBHSV in indirect ELISA
assays.
MAb RHDV RHDV2 EBHSV Epitope location (aa position within VP60
protein)
2E7 + + + (aa 549-579, P1 subdomain)
1G5 + + - NPISQVAP (aa 326-333, loop 2 at P2
subdomain)
1C9a + - - PGNNAT (aa 305-310, loop 1 at P2
subdomain)
+ Positive reaction; - Negative reaction.
a 1C9 is a conformational epitope. It does not bind to RHDV VLPs derived from
VP60 deletion or insertion mutants lacking the sequence corresponding to aa
positions 305-310 of VP60 protein.(goat anti-rabbit IgG (H + L) HRP-conjugate; Thermo
Fisher Scientific) was used at 1/3000 dilution, followed by
addition of substrate solution (OPD (o-phenylenediamine
dihydrochloride); Invitrogen). The reaction was stopped
by addition of 3 N H2SO4, and color development was re-
corded at 492 nm. In Figure 2A, sera titres are represented
as dots with their x-axis value corresponding to the titre
obtained against RHDV VLPs and the y-axis value to the
titre obtained against RHDV2 VLPs. All sera tested
showed higher antibody titres against RHDV VLPs, their
cognate antigen, than against RHDV2 VLPs, as indicated
by the fact that the titre levels obtained were all situated
below the diagonal line represented on the graph.
Using the same approach (with a dilution range
starting from 1/30), we tested sera from rabbits vacci-
nated against RHDV (ARVILAP vaccine, Laboratorios
Ovejero, Spain) or RHDV2 (NOVARVILAP vaccine,
Laboratorios Ovejero, Spain or FILAVAC VHD VARI-
ANT vaccine, Filavie, France) collected 21 days after
vaccination (Figure 2B). All animals developed specific
antibody responses which were consistently higher for
the cognate than for the heterologous antigen. Taken
together, the results obtained revealed a markedly dif-
ferent antigenicity between both viral capsids, which
is consistent with the observed lack of efficient pro-
tection afforded by current commercial RHDV vac-
cines against RHDV2.
Finally, we used both RHDV and RHDV2 VLPs to
screen by ELISA a set of 180 serum samples collected
from a wild rabbit population during April-November
2014, in a region of Central Spain (Ciudad Real).
Figure 3A shows the results obtained when a single dilu-
tion (1/500) of each serum sample was tested. A high
prevalence of antibodies to lagoviruses was detected
Figure 2 Antibody responses in RHDV and RHDV2 vaccinated rabbits analyzed by indirect ELISA. A Titres of sera (n = 4) from rabbits
immunized with RHDV VLPs. Each sample is represented on a coordinate graph showing its titre for RHDV on the x-axis and for RHDV2 on the y-axis.
For the determination of serum titres, seven serial three-fold dilutions starting from 1/10 000 were tested by ELISA for reactivity against RHDV and
RHDV2 VLPs independently in duplicate samples. OD measurements were blank-corrected and titre extrapolated as the dilution at which they reached
an arbitrary OD value (0.240) corresponding to that obtained by the mean + 2 times the standard deviation of 12 serum samples from non-vaccinated
animals assayed at a 1/30 dilution. This OD value was initially established as threshold to classify each serum as negative or positive. All calculations
were performed using GraphPad software. B Titres of sera from 8 week old rabbits vaccinated with ARVILAP (n = 2) or 4 week old rabbits vaccinated
with FILAVAC (n = 5) or NOVARVILAP (n = 5), respectively. ELISA assays were performed as described above using a dilution range starting from 1/30.
Representation and calculations are as in panel A. Procedures involving obtainment of animal samples were carried out under EU guidelines and
supervised and approved by the institutional ethical review committee.
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lyzed, with more than 91% of the sera samples reacting
with RHDV VLPs and 95% with RHDV2 VLPs. The
mean signal obtained was significantly higher when
RHDV2 VLPs were used as antigen, a difference which
was most likely an underestimate, given the largeFigure 3 Prevalence of anti-RHDV and anti-RHDV2 antibodies in a wil
180 sera from wild rabbits captured in a region of Central Spain (Ciudad Real)
using plates coated with RHDV or RHDV2 VLPs. A single dilution (1/500) of ea
represented as two separate groups. A line at an arbitrary value (0.155) corres
from non vaccinated animals at the same dilution is shown. Mean plus SD are
significant difference (p < 0.0001) as assessed by a paired t-test. B Representat
and 1/2700) of 15 selected sera from the same collection. ELISAs were perform
highlight sera samples showing reactivity with RHDV2 but not with RHDV VLP
under EU guidelines and supervised and approved by the institutional ethicalfraction of saturated samples in this assay. Importantly,
7 serum samples were shown to react with RHDV2 but
not with RHDV-VLPs under the ELISA conditions used.
A more detailed analysis (three different dilutions of
each sample: 1/300, 1/900 and 1/2700) was performed
with 15 randomly selected sera samples (Figure 3B). Ofd rabbit population analyzed by indirect ELISA. A A collection of
during the months of April and November 2014 was tested by ELISA
ch sample was tested and recorded OD values for each sample are
ponding to the mean OD+ 2 times the standard deviation of 10 samples
indicated for each antigen group. Asterisks indicate a statistically
ion of OD values obtained using three different dilutions (1/300, 1/900
ed in duplicate under the same conditions indicated above. Arrows
s. Procedures involving obtainment of animal samples were carried out
review committee.
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lutions. Sera from two animals reacted with RHDV2
VLPs but not with RHDV VLPs, while of the remaining
nine, five showed higher signal to RHDV2 than to
RHDV and four had comparable reactivity. None of the
analysed sera showed higher titres towards RHDV than
to RHDV2. Overall, the results obtained suggested that
the novel virus RHDV2 had circulated among the stud-
ied wild rabbit population, being responsible for at least
great part if not all of the observed seroconversion.
Discussion
The available information regarding sequence alignment
studies of lagovirus full-length capsid proteins indicate
RHDV2 is phylogenetically distinct from all previously
described members of the genus Lagovirus and forms a
new genetic group [14]. Amino acid identity among
RHDV2 strains is close to 97%, whereas average identity
is 89.2% when compared with RHDV strains [14,17].
When the sequence comparison is restricted to the 7 re-
gions of the P domain that show the highest degree of
genetic variation (regions V1 to V7 [12]), the identity be-
tween RHDV2 and RHDV strains drops to 60% [14].
Moreover, the crystallographic resolution of the VP60
protruding P domains of RHDV [12] and RHDV2 [29],
has enabled the analysis of structural differences be-
tween both viruses. Although their overall structures are
similar, the P1 subdomain helices are slightly shifted and
some P2 subdomain loops are oriented differently. Inter-
estingly, amino acid changes between both viral capsid
proteins tend to concentrate on the three extended loop
regions located at the outer surface of the P2 subdomain
[29]. These results provide insights regarding the marked
antigenic differences observed between both viruses, re-
markably the lack of efficient protection against RHDV2
afforded by current RHDV inactivated vaccines, which
has prompted the urgent development and provisional
authorization of RHDV2-specific inactivated vaccines.
Epidemiological surveillance of RHD among domestic
and wild rabbit populations is performed using sero-
logical assays based on the use of RHDV antigen ob-
tained from infected-rabbit liver extracts and virus
specific MAbs [4-6]. Commercial test kits based on
RHDV VLPs are currently available and have been used
in several studies [16,30]. In Australia, early seroepide-
miologic surveys [7] evidenced the circulation of a non-
pathogenic rabbit calicivirus (RCV-A1), which was sub-
sequently identified and characterized [2]. Serological as-
says enabling discrimination of both viruses, based on
the use of virus specific VLPs, have been developed [11].
In Europe, the rapid spread of the newly emergent virus
RHDV2, which is apparently replacing classical RHDV
strains among rabbit populations [14,18] and is capable
of infecting lagomorphs from the Lepus genus [17,22], isa major cause of concern. The availability of virus spe-
cific reagents such as RHDV2 VLPs, would greatly ease
monitorization of field evolution and circulation of
RHDV2, as well as its interaction with RHDV when both
viruses co-circulate in rabbit populations.
Here we report for the first time the generation and
characterization of RHDV2-specific VLPs. Our results
further confirmed the differential antigenic properties
exhibited by RHDV and RHDV2 capsid proteins. Using
sera from both, vaccinated and infected rabbits, it was
shown that antibody responses were consistently higher
for the cognate than for the heterologous antigen. Inter-
estingly, the results obtained in the serological analysis
of sera collected from an apparently healthy wild rabbit
population from Central Spain, suggesting high preva-
lence of RHDV2, were in agreement with previous re-
ports indicating rapid spread of the novel virus through
the Iberian Peninsula [16,23].
The VLPs reported in this study might also be useful
for the development of vaccines against RHDV2.
Current provisionally authorised vaccines for RHDV2
are prepared from liver extracts of experimentally in-
fected rabbits. Since RHDV2 induces consistently low
mortality rates (20-30%) as compared to RHDV (close to
100%), this might represent an important drawback for
vaccine production (i.e. lower yields of virus antigen per
infected rabbit). Therefore, the development of new re-
combinant subunit vaccines for RHDV2 based on VLPs
might provide greater benefit than the equivalent for
RHDV.
In addition, this work enabled the characterization of
our MAbs 2E7, 1G5 and 1C9, regarding their differential
reactivity with three lagovirus capsid proteins (RHDV,
RHDV2 and EBHSV). In summary, the RHDV2 VLPs
and the MAbs reported in this study provide tools that
might be useful for monitorization of virus circulation,
development of control measures, as well as for research
in different aspects of the biology of this relevant emer-
gent virus.
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